GIGABYTE
17.5.2023 03:31:33 CEST | Business Wire | Press release
GIGABYTE, a leading innovator of computer hardware and server solutions, announces its unprecedented exhibits at COMPUTEX 2023. Resonating its theme “Future of COMPUTING”, GIGABYTE is unveiling its all-around technical achievements, including industry-leading AI/HPC servers, green computing solutions, gaming and creator products, industrial PC, AI smart securities, and autonomous vehicle technology.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230516005112/en/
GIGABYTE to Introduce Leading-Edge AI Solutions and Computers at COMPUTEX 2023, Unveiling “Future of COMPUTING” (Graphic: Business Wire)
Besides product exhibits, GIGABYTE will hold a four-day Tech Talk with speakers from AMD, Ampere, Intel, and NVIDIA, sharing insights about how the future of computing is reshaping the technology landscapes. The exhibition will be held from May 30th to June 2nd on the 1st floor, Taipei Nangang Exhibition Center, Hall 1.
Take the Lead in the AI Era with GIGABYTE’s Trailblazing GPU/HPC Servers
The emergence of ChatGPT and various generative AI applications are making huge waves of industry evolution, driving all-time demand for AI computing servers. At COMPUTEX, GIGABYTE and its subsidiary, Giga Computing, are unveiling a cutting-edge lineup of GPU-accelerated servers and HPC servers. These solutions are aimed at accelerating exascale data analysis, deep learning, machine learning, inferencing, large language models (LLM), and generative AI training tasks, unlocking the unparalleled breakthroughs of AI development.
The latest lineup of GPU/HPC server solutions is powered by the latest CPU platform, GPU accelerator cards, and AI deep learning and inference technologies from leading tech partners. With GIGABYTE’s exclusive density-optimized server design and cooling technology, AI computing servers can achieve superior performance and energy efficiency, allowing enterprises and institutes to become the front-runner in AI competition.
Strike the Goals of Data Center Sustainability with GIGABYTE’s Immersion Cooling Solutions
The advent of AI technology has raised concerns about surging electricity consumption and carbon emissions, leading to the growing demand for data center cooling solutions designed to save power, boost computing performance, and reduce total cost of ownership (TCO). For the first time, GIGABYTE is showcasing three models of immersion cooling tanks and corresponding server series, demonstrating its widely acclaimed green computing solutions at COMPUTEX.
GIGABYTE's immersion cooling solutions have established admirable standards in energy efficiency and cost-effectiveness; therefore, they have been adopted by global semiconductor giants, telecommunication services, and European top research centers. GIGABYTE’s self-developed total solutions include the immersion cooling tanks, server configuration designs, and automatic monitoring and adjustment mechanisms, allowing enterprises and institutions to embrace sustainability and achieve innovation breakthroughs.
Explore the Gaming and Creator Computers with Lightspeed Overlocking
In addition to enterprise solutions, GIGABYTE is exhibiting a comprehensive computer portfolio, including the 2023 Red Dot Design Award-winning AORUS and AERO motherboards, graphics cards, and laptops, as well as STEALTH 500 computer assembly kit that won CES Innovation Award, SSD and large-size 4K monitors. All of these demonstrate GIGABYTE’s technical prowess and exceptional aesthetics. Tech enthusiasts at the booth will be thrilled to explore how GIGABYTE’s computers are pushing the performance beyond the limits and offering immersive experiences.
Grasp the Insights of Industry-Leading AI Trends at GIGABYTE Tech Talk
During the four-day COMPUTEX exhibition, GIGABYTE’s booth is holding Tech Talk sessions with diverse topics. Speakers from technology giants will share first-hand insights of AI advancements and green computing technologies, delivering various perspectives of “Future of COMPUTING” to the audiences.
Visit GIGABYTE’s COMPUTEX event page.
Subscribe to GIGABYTE newsletter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230516005112/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom